New drug could shrink rare liver tumors, spare women from surgery
NCT ID NCT06490757
First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tests a JAK1 inhibitor drug (baricitinib) to shrink large inflammatory hepatocellular adenomas (liver tumors) in 25 people. These tumors are rare, often affect young women on birth control, and usually require surgery when larger than 5 cm. The goal is to see if a short course of the drug can reduce tumor size enough to avoid surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY HEPATOCELLULAR ADENOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NAULT
RECRUITINGBobigny, 93000, France
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.